Awaiting development: Guidance and quality standards

Showing 211 to 220 of 294

Guidance and quality standards awaiting development
Title	Type
Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [TS ID 12097]	Technology appraisal guidance
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764	Technology appraisal guidance
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763	Technology appraisal guidance
Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]	Technology appraisal guidance
Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]	Technology appraisal guidance
Sabizabulin for treating COVID 19 TS ID 11814	Technology appraisal guidance
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433	Technology appraisal guidance